GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00068987 | Cervix | CC | receptor-mediated endocytosis | 53/2311 | 244/18723 | 2.52e-05 | 4.29e-04 | 53 |
GO:00301008 | Cervix | CC | regulation of endocytosis | 47/2311 | 211/18723 | 3.65e-05 | 5.82e-04 | 47 |
GO:00725836 | Cervix | CC | clathrin-dependent endocytosis | 16/2311 | 47/18723 | 9.56e-05 | 1.25e-03 | 16 |
GO:00482597 | Cervix | CC | regulation of receptor-mediated endocytosis | 24/2311 | 110/18723 | 3.62e-03 | 2.31e-02 | 24 |
GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
GO:0001890110 | Esophagus | ESCC | placenta development | 98/8552 | 144/18723 | 4.46e-08 | 8.11e-07 | 98 |
GO:003010018 | Esophagus | ESCC | regulation of endocytosis | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
GO:00097919 | Esophagus | ESCC | post-embryonic development | 56/8552 | 80/18723 | 9.08e-06 | 8.71e-05 | 56 |
GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
GO:000689818 | Esophagus | ESCC | receptor-mediated endocytosis | 142/8552 | 244/18723 | 5.22e-05 | 4.05e-04 | 142 |
GO:007258314 | Esophagus | ESCC | clathrin-dependent endocytosis | 34/8552 | 47/18723 | 1.91e-04 | 1.21e-03 | 34 |
GO:00352647 | Esophagus | ESCC | multicellular organism growth | 80/8552 | 132/18723 | 3.84e-04 | 2.22e-03 | 80 |
GO:0006646 | Esophagus | ESCC | phosphatidylethanolamine biosynthetic process | 10/8552 | 10/18723 | 3.94e-04 | 2.26e-03 | 10 |
GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNK2 | SNV | Missense_Mutation | novel | c.2996N>A | p.Ala999Asp | p.A999D | Q07912 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.967) | TCGA-LL-A5YL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TNK2 | SNV | Missense_Mutation | novel | c.2995N>A | p.Ala999Thr | p.A999T | Q07912 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.859) | TCGA-LL-A5YL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TNK2 | insertion | Frame_Shift_Ins | novel | c.703_704insCTCTGGAAAGCCT | p.Asp235AlafsTer52 | p.D235Afs*52 | Q07912 | protein_coding | | | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
TNK2 | deletion | Frame_Shift_Del | novel | c.402delN | p.Lys134AsnfsTer6 | p.K134Nfs*6 | Q07912 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
TNK2 | SNV | Missense_Mutation | novel | c.1672N>A | p.Asp558Asn | p.D558N | Q07912 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TNK2 | SNV | Missense_Mutation | rs559677615 | c.2309N>T | p.Gln770Leu | p.Q770L | Q07912 | protein_coding | tolerated_low_confidence(0.16) | benign(0.21) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
TNK2 | SNV | Missense_Mutation | rs143850445 | c.2824N>A | p.Glu942Lys | p.E942K | Q07912 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.994) | TCGA-EK-A2R7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TNK2 | SNV | Missense_Mutation | | c.1069N>C | p.Phe357Leu | p.F357L | Q07912 | protein_coding | deleterious(0.01) | probably_damaging(0.948) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
TNK2 | SNV | Missense_Mutation | rs756000040 | c.749N>A | p.Arg250Gln | p.R250Q | Q07912 | protein_coding | tolerated(0.98) | benign(0.006) | TCGA-HM-A3JK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
TNK2 | SNV | Missense_Mutation | rs748682309 | c.901G>A | p.Glu301Lys | p.E301K | Q07912 | protein_coding | tolerated(0.92) | benign(0.019) | TCGA-MU-A8JM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10188 | TNK2 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME | | CYC-116 | CYC-116 | |
10188 | TNK2 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME | | ILORASERTIB | ILORASERTIB | |
10188 | TNK2 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME | | AZD-1775 | ADAVOSERTIB | |
10188 | TNK2 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME | | CENISERTIB | CENISERTIB | |
10188 | TNK2 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME | | PF-562271 | PF-00562271 | |
10188 | TNK2 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME | inhibitor | 249565873 | | |
10188 | TNK2 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME | | ZM-447439 | CHEMBL202721 | |
10188 | TNK2 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME | | DASATINIB | DASATINIB | |
10188 | TNK2 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME | | ALISERTIB | ALISERTIB | |
10188 | TNK2 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME | | RG-1530 | RG-1530 | |